Royce & Associates LP acquired a new stake in Celcuity, Inc. (NASDAQ:CELC) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 112,000 shares of the company’s stock, valued at approximately $1,371,000. Royce & Associates LP owned approximately 1.15% of Celcuity as of its most recent filing with the Securities & Exchange Commission.
Separately, Essex Investment Management Co. LLC acquired a new position in Celcuity during the 3rd quarter worth approximately $184,000. Institutional investors and hedge funds own 13.26% of the company’s stock.
In other Celcuity news, Director Richard Nigon purchased 7,500 shares of Celcuity stock in a transaction that occurred on Tuesday, November 28th. The stock was purchased at an average price of $17.48 per share, for a total transaction of $131,100.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Separately, Craig Hallum began coverage on shares of Celcuity in a report on Monday, October 16th. They issued a “buy” rating for the company.
Shares of Celcuity, Inc. (NASDAQ:CELC) traded up $0.14 during trading on Friday, hitting $19.64. 28,673 shares of the stock traded hands, compared to its average volume of 33,354. Celcuity, Inc. has a fifty-two week low of $11.10 and a fifty-two week high of $22.73.
COPYRIGHT VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/112000-shares-in-celcuity-inc-celc-purchased-by-royce-associates-lp.html.
Celcuity, Inc is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.